ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Merus NV

Merus NV (2GH)

42.20
0.80
(1.93%)
Closed December 07 4:00PM
Realtime Data

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
42.20
Bid
41.80
Ask
42.80
Volume
0.00
0.00 Day's Range 0.00
21.40 52 Week Range 58.50
Previous Close
41.40
Open
-
Last Trade
Last Trade Time
Average Volume (3m)
127
Financial Volume
-
VWAP
-

2GH Latest News

Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC

Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC Petosemtamab in combination with pembrolizumab in 1L r/m PD-L1 expressing...

Merus gibt FDA-Zulassung von BIZENGRI® (Zenocutuzumab-zbco) für NRG1+-Adenokarzinome der Bauchspeicheldrüse und NRG1+-nicht-kleinzelligen Lungenkrebs (NSCLC) auf der Grundlage von Sicherheits- und Wirksamkeitsdaten aus der eNRGy-Studie bekannt

Merus gibt FDA-Zulassung von BIZENGRI® (Zenocutuzumab-zbco) für NRG1+-Adenokarzinome der Bauchspeicheldrüse und NRG1+-nicht-kleinzelligen Lungenkrebs (NSCLC) auf der Grundlage von Sicherheits- und...

Merus annonce l’autorisation par la FDA de BIZENGRI® (zénocutuzumab-zbco) dans le traitement de l’adénocarcinome pancréatique NRG1+ et du cancer du poumon non à petites cellules (CPNPC) NRG1+, en fonction des données de sécurité et d’efficaci

Merus annonce l’autorisation par la FDA de BIZENGRI® (zénocutuzumab-zbco) dans le traitement de l’adénocarcinome pancréatique NRG1+ et du cancer du poumon non à petites cellules (CPNPC) NRG1+, en...

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy...

Merus und Partner Therapeutics geben Lizenzvereinbarung für die Vermarktung von Zenocutuzumab in den USA bei NRG1-fusionspositivem Krebs bekannt

Merus und Partner Therapeutics geben Lizenzvereinbarung für die Vermarktung von Zenocutuzumab in den USA bei NRG1-fusionspositivem Krebs bekannt UTRECHT, Niederlande, und CAMBRIDGE, Massachusetts...

Merus et Partner Therapeutics annoncent un contrat de licence en vue de la commercialisation aux États-Unis du zenocutuzumab dans le cadre du traitement des cancers à fusion NRG1 positive

Merus et Partner Therapeutics annoncent un contrat de licence en vue de la commercialisation aux États-Unis du zenocutuzumab dans le cadre du traitement des cancers à fusion NRG1 positive UTRECHT...

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 02...

Merus annonce la publication d’un résumé sur le pétosemtamab en tant que traitement de 2e ligne et au-delà pour le CETC r/m lors de l’édition 2024 du Congrès de l’ESMO Asia

Merus annonce la publication d’un résumé sur le pétosemtamab en tant que traitement de 2e ligne et au-delà pour le CETC r/m lors de l’édition 2024 du Congrès de l’ESMO Asia – Les données...

Merus gibt am ESMO-Kongress 2024 in Asien die Veröffentlichung eines Abstracts zur Behandlung von rezidivierenden/metastasierten Kopf- und Halstumoren ab der zweiten Behandlungslinie mit Petosemtamab bekannt

Merus gibt am ESMO-Kongress 2024 in Asien die Veröffentlichung eines Abstracts zur Behandlung von rezidivierenden/metastasierten Kopf- und Halstumoren ab der zweiten Behandlungslinie mit...

Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024

Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024 – Petosemtamab 1500 mg monotherapy phase 2 interim data continues to...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-1-2.3148148148143.2474319244.19451697DE
4-7.8-15.65051.540.411744.74603537DE
12-3-6.6371681415945.251.540.412747.17167127DE
26-6-12.448132780148.257.540.415948.57608533DE
5219.283.47826086962358.521.39999917344.34418355DE
15618.477.310924369723.858.51916742.00023485DE
26018.477.310924369723.858.51916742.00023485DE

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
TE9Teco 2030 ASA
0.0592 €
(65.36%)
2.11M
A6NAsana Inc
21.00 €
(43.84%)
19.08k
NL8Genesis Ai Corp
0.0214 €
(40.79%)
13.33k
RQ0DWave Quantum Inc
4.814 €
(34.92%)
1.15M
K8DWellfield Technologies Inc
0.0342 €
(34.65%)
30.8k
AXIAtos SE
0.0028 €
(-98.58%)
1.59B
M0YNMynaric AG
1.40 €
(-72.66%)
303.13k
W47Grid Battery Metals Inc
0.0115 €
(-39.47%)
7
47GAGo Metals Corp
0.0202 €
(-36.88%)
3.44k
4APApollo Minerals Ltd
0.0055 €
(-35.29%)
270.7k
AXIAtos SE
0.0028 €
(-98.58%)
1.59B
D7GNel ASA
0.2625 €
(-1.69%)
4.24M
LK1Lake Resources
0.029 €
(-6.75%)
2.32M
TUI1Tui AG
8.40 €
(1.11%)
2.17M
TE9Teco 2030 ASA
0.0592 €
(65.36%)
2.11M

Discussion

View Full Feed
3331 3331 50 seconds ago
BIEL POPS MONDAY!
TenKay TenKay 51 seconds ago
Something about there being a “pile of fertilizer” somewhere in Brazil associated with this seems so … apropos!!!

LOL. Can’t make this stuff up.
HMBL
CC88Trade CC88Trade 55 seconds ago
Yes they did, they clearly stated they will share after their acquisition
SDRC
dinogreeves dinogreeves 1 minute ago
https://investorshub.advfn.com/uimage/uploads/2024/12/7/lmjqzD5C0CB01-C3CA-48A0-8B78-83AE107F524D.webp
SMCI
sliceanddice59 sliceanddice59 1 minute ago
Thanks.
AVXL
dinogreeves dinogreeves 2 minutes ago
"Finally got its billion dollar mc. But we know it should be many billions. I can see it going to $50+ on a frenzy when people fomo over the "most powerful quantum computer" play.
Bullish"
QBTS
1vman 1vman 2 minutes ago
***** 🚽HCWC🚽 Sales down , volume shriveling up , So much for Mother Earth’s Stores

not l👀king good here - Wh👀ps

HUZZAH🤔 !!! ENOUGH SAID😃 !!!
HCWC
1vman 1vman 3 minutes ago
***** 🤪Huge🚽UBQU🚽share structure here - VERY concerning

ENOUGH SAID HUZZAH🤪 !!!
UBQU
dinogreeves dinogreeves 3 minutes ago
"here u go guys, 4000 qbit with dwave suceed , highest of all. let me help u all again. i see 30 percent up or more early monday. i expext 12 dollars this week, dwave has highest qbit of all right now , u heard here first, dont be shock if dwave mc will surpass ionq when gorverment conyract land w
QBTS
catdaddy catdaddy 4 minutes ago
How to Win Friends and Influence People. Good book. You ought to try it!
AVXL
dinogreeves dinogreeves 4 minutes ago
ST is all going crazy on this tech.

"guys loading up with all your money, bitcoin miner is biggggggggg, they are looking to replace all classic computers now , 1 quantum computer = 100k classic computer plus cost energy , less service. and all networking and storage will order dwav
QBTS
WhenLambo WhenLambo 4 minutes ago
Let’s go TPTW! 🚀
TPTW
OMOLIVES OMOLIVES 4 minutes ago
You'll be able to trade it effectively when it becomes solicited.
DROR
3331 3331 4 minutes ago
BIEL: #9 BREAKOUT BOARD - GOLDEN COSS BLUE SKY BREAKOUT!
1vman 1vman 5 minutes ago
*****🟥🟥🟥 HCMC Heading back to the expert market , poorly run company here IMO

ENOUGH SAID HUZZAH !!! 🤪
HCMC
3331 3331 6 minutes ago
BIEL: #9 BREAKOUT BOARD - GOLDEN COSS BLUE SKY BREAKOUT!
1vman 1vman 6 minutes ago
*****🟥🟥🟥 DBMMs PEO Linda needs to explain under oath in a court room the discrepancies of salary collected in financials 👍️👍️👍️-- whoops

ENOUGH SAID HUZZAH🤔 !!!
DBMM
Lime Time Lime Time 7 minutes ago
Huge opportunity exists here
BCAP
igotthemojo igotthemojo 7 minutes ago
"First off, those are the words of the Scumbag CEO, and not Mr Kumar."

Dr Kumar concurred with Kim...

from Dr Kumar:

" In 2025 production will be multi-ton spider silk"
KBLB
trader59 trader59 8 minutes ago
There's another characteristic of a stalking horse bid:  they document that bid in the court records letting everyone, including the other bidders, the creditors, the judge, and the public, know about it. 
For this bankruptcy, they documented the purchase price, $4.34M for the assets. That's
3331 3331 8 minutes ago
BIEL: SALONPAS WILL LOSE IT'S $200 MILLION US MARKET TO ACTIPATCH!
BDEZ BDEZ 9 minutes ago
Exactly 02...
EarningsCentral EarningsCentral 9 minutes ago
GTLB
MasterBlastr MasterBlastr 9 minutes ago
Just as he went on 59 watch, he hits it in the trap on 17. Oh well. Let's see if Homa can right the ship over on DPW.

Your Recent History

Delayed Upgrade Clock